Gender-Affirming Hormone Therapy: Key Drug Interactions and Side Effects to Watch For

When someone starts gender-affirming hormone therapy (GAHT), they’re not just changing their hormones-they’re changing how their body processes every other medication they take. This isn’t theoretical. It’s real, measurable, and sometimes life-changing. A transgender woman on estradiol who starts HIV treatment might suddenly feel like her hormones aren’t working. A transgender man on testosterone who begins an antidepressant might notice his mood dips even though the dose hasn’t changed. These aren’t coincidences. They’re drug interactions, and they’re more common than most providers realize.

How GAHT Works-And Why It Interacts

Gender-affirming hormone therapy comes in two main forms: feminizing therapy for transgender women and nonbinary people assigned male at birth, and masculinizing therapy for transgender men and nonbinary people assigned female at birth. Feminizing therapy usually includes estradiol and an anti-androgen like spironolactone or cyproterone acetate. Masculinizing therapy typically uses testosterone in gel, injection, or pellet form. Both types affect how your liver and intestines break down other drugs.

The key to understanding interactions lies in enzyme systems-especially CYP3A4 and CYP2D6. These are the body’s main drug-processing factories. Estradiol is mainly broken down by CYP3A4. That means anything that boosts or blocks this enzyme will change how much estradiol stays in your bloodstream. Testosterone, on the other hand, is handled by different pathways, including 5-alpha reductase and aromatase, which makes its interactions less predictable but still significant.

Antiretroviral Therapy: A Critical Intersection

Transgender people are 3.4 times more likely to be living with HIV than cisgender people, according to the 2021 National Transgender Survey. That means many people on GAHT are also taking antiretroviral therapy (ART). This overlap is where things get complicated-and dangerous if ignored.

Some HIV drugs, like efavirenz (600 mg daily), are enzyme inducers. They speed up CYP3A4, which can drop estradiol levels by 30-50%. That means a transgender woman might lose breast development, experience hot flashes, or even start ovulating again-despite taking her usual dose. In one case report, a woman’s estradiol level fell from 200 pg/mL to 45 pg/mL after starting efavirenz.

On the flip side, drugs like cobicistat-boosted darunavir (800/150 mg daily) block CYP3A4. This can cause estradiol to build up dangerously, increasing the risk of blood clots, stroke, or liver strain. Studies show estradiol levels can spike 40-60% within two weeks of starting these regimens. The fix? Don’t change the hormone dose right away. Monitor levels at 2 and 6 weeks after starting ART. Adjust only if symptoms appear.

The good news? Dolutegravir (50 mg daily), an integrase inhibitor, shows no clinically significant interactions with estradiol. It’s now the preferred first-line ART for people on feminizing hormones. For testosterone users, no major ART interactions have been documented. GnRH agonists like leuprolide acetate also don’t interfere with any HIV drugs-making them a safe option for those needing puberty suppression or hormone control.

PrEP and GAHT: No Need to Worry

Pre-exposure prophylaxis (PrEP) is vital for HIV prevention. The most common form, tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), has been studied in over 170 transgender people. The 2022 CROI study found no meaningful changes in hormone levels or drug concentrations. Estradiol and testosterone stayed within normal ranges. Tenofovir levels in blood stayed stable too.

Even better: researchers used dried blood spot tests to confirm that 92.4% of participants maintained protective levels of tenofovir diphosphate throughout the 12-week study. That means you can take PrEP and GAHT together without dose changes, monitoring, or fear of reduced protection. This is one of the clearest, most reassuring findings in recent transgender health research.

Psychiatric Medications: The Hidden Risk

Transgender individuals are 2.5 times more likely to experience depression, anxiety, or suicidal ideation. That means many are on SSRIs, SNRIs, or mood stabilizers. But here’s the problem: we don’t have enough data.

Fluoxetine (20-80 mg daily) and other SSRIs can inhibit CYP2D6, which may raise estradiol levels slightly. Not enough to cause harm in most cases, but enough to be noticed-especially in people sensitive to estrogen. One study found 17 cases (0.14% of patients) where testosterone therapy reduced antidepressant effectiveness. Patients reported worsening mood, fatigue, or lack of motivation. In every case, increasing the antidepressant dose by 25-50% within six weeks restored symptom control.

Worse are enzyme-inducing psychiatric drugs like carbamazepine (200-1200 mg daily) and phenytoin. These can slash estradiol levels by up to 40%, leading to loss of feminizing effects. Testosterone levels may also drop, though evidence is sparse. The 2023 UCSF/Harvard review noted that only 3% of antidepressant trials include transgender participants. That’s not just a gap-it’s a risk.

Bottom line: Don’t assume psychiatric meds work the same way after starting GAHT. Track your mood, energy, and sleep. If things change, talk to your prescriber. Don’t stop your meds. Adjust them.

Other Common Medications to Watch

Many everyday drugs can interfere with GAHT, even if they seem harmless.

• St. John’s Wort-a popular herbal supplement for depression-is a powerful CYP3A4 inducer. It can make estradiol ineffective. Avoid it entirely.
• Grapefruit juice blocks CYP3A4. If you’re on oral estradiol, drinking grapefruit juice daily can cause hormone levels to spike unpredictably. Stick to water or orange juice.
• Statins like atorvastatin are metabolized by CYP3A4. Combining them with estradiol may increase muscle pain or liver enzyme elevations. Monitor liver tests every 3 months.
• Thyroid medications like levothyroxine may need dose adjustments after starting testosterone, as testosterone increases sex hormone-binding globulin (SHBG), which alters free hormone availability.

Even antibiotics like rifampin (used for tuberculosis) can reduce estradiol levels by over 50%. Always tell your provider you’re on GAHT before starting any new medication-even over-the-counter ones.

What Should You Do?

Here’s a simple action plan:

1. Make a full list of every medication, supplement, and herb you take-including doses and frequency.
2. Bring it to every appointment with your endocrinologist, HIV provider, psychiatrist, or primary care doctor.
3. Ask directly: "Could this interact with my hormones?" Don’t assume they know.
4. Get hormone levels checked 4-6 weeks after starting any new drug that affects the liver (especially HIV meds, antiseizure drugs, or antibiotics).
5. Track symptoms like mood changes, breast tenderness, fatigue, or unexpected bleeding. These are early warnings.

Most importantly: don’t stop your hormones or your other meds without talking to your care team. The risks of untreated depression, HIV, or hormone imbalance are far greater than the risk of an interaction.

Where the Science Is Headed

Research is catching up. The NIH-funded Tangerine Study is tracking 300 transgender adults taking 12 common psychiatric drugs alongside GAHT. Results are expected in mid-2025. Gilead Sciences now requires GAHT interaction testing in all new PrEP trials. The FDA is pushing for more inclusive clinical trials.

But until we have more data, the rule is simple: assume interactions are possible. Monitor. Adjust. Communicate. The goal isn’t to scare you-it’s to make sure your treatment works as it should. Your body deserves that level of care.